Condition: Advanced Chronic Myeloid Leukemia · Philadelphia Chromosome-Positive Acute Myeloid Leukemia · Sponsor: M.D. Anderson Cancer Center
To find the recommended doses of lisaftoclax and olverembatinib that can be given in combination with decitabine to participants with advanced CML and Ph+ AML.
This description comes directly from the study's public registry record.
Nicholas Short, MD · (713) 563-4485 · nshort@mdanderson.org
Always discuss trial participation with your own doctor first.
| MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06401603